| Objective:To retrospectively the efficacy and drug safety of Roxadustat capsules in the treatment of chronic kidney disease with renal anemia。Methods:Sixty-one patients with chronic kidney disease complicated with renal anemia and met the inclusion criteria,were selected from China-Japan Union Hospital of Jilin University from September 2019 to March 2021.They were divided into control group（31 cases）and experimental group（30 cases）,with ratio of male to female was 41/20,and the age ranged from 30 to 79 years old,and an average age of 60.05±14.60 years old.The control group was treated with Recombinant human erythropoietin,and the experimental group was treated with Roxadustat capsule.SPSS 21.0 statistical software was used for statistical analysis of the data,and T test,analysis of variance and χ2 test were used to compare the changes of anemia,iron metabolism,ions,blood lipid related indicators in the two groups at different time points,and incidence of adverse reactions.Result:1.Sixty-one patients with chronic kidney disease and renal anemia were enrolled and divided into two groups.General data between the experimental group and the control group,such as gender,age,height,weight,CKD stage,systolic blood pressure,diastolic blood pressure,basic diseases,and laboratory data before treatment,such as red blood cell count,hemoglobin,hematocrit,serum ferritin,transferrin saturation,total cholesterol,triglyceride,high density lipoprotein cholesterol,low density lipoprotein cholesterol,serum potassium were not significantly different.2.Indicators related to anemia:Hct and Hb level in both groups increased after12 weeks of observation,and Hb and Hct levels in the experimental group were higher than those in the control group at 4 weeks,8 weeks and 12 weeks,the difference was statistically significant（P<0.05）.3.Hb response（refers to the increase in hemoglobin after treatment Hb>10g/L）:After 4 weeks of observation,Hb response achieved in the experimental group was39.1% higher than that in the control group,and the difference was statistically significant（P<0.01）,Hb response achieved in the experimental group remained above 90% after 8 and 12 weeks of observation,and there was no statistically significant difference between the two groups（P>0.05）.4.Indicators related to iron metabolism : Fe,SF and TSAT levels in both groups increased after 12 weeks of observation,and Fe and TSAT levels in the experimental group were higher than those in the control group at 4 weeks,8 weeks and 12 weeks,while SF levels in the experimental group were higher than those in the control group at 8 weeks and 12 weeks,the difference was statistically significant（P<0.05）.5.Indicators related lipid metabolism:TC,TG and LDL-C was lower and HDL-C was higher than before treatment in the experimental group at 12 weeks（P<0.05）;There was no significant difference in the above indicators before and after treatment in the control group（P>0.05）.6.Ion-related indicators: potassium ion level in experimental group increased after 12 weeks of observation,while there was no significant change in the observation group.At 12 weeks of observation,the increase of potassium ion water in experimental group was higher than that in control group on average,and the differences were statistically significant（P<0.05）.7.In non-dialysis patients,the increase of Hct,Hb,SF and TSAT levels and the decrease of LDL-C levels of Roxadustat at 12 weeks was higher than that of r Hu EPO.In dialysis patients,the increase of HDL-C and potassium ion levels of Roxadustat at 12 weeks was higher than that of r Hu EPO,and the incidence of adverse reactions was lower than that of r Hu EPO,the differences were statistically significant（P<0.05）.8.During the follow-up period,the adverse reactions in the experimental group were mainly upper respiratory tract infection,and the adverse reactions in the control group were mainly hypertension,upper respiratory tract infection.The incidence of adverse reactions in the experimental group was lower than that in the control group,and there was no statistical significance between the groups（P>0.05）.Conclusion:1.Roxadustat and rHuEPO are both effective in the treatment of patients with chronic kidney disease complicated with renal anemia,and Roxadustat has the advantage of regulating iron metabolism and lipid metabolism with faster onset and better effect.Compared with r Hu EPO,there is no significant difference in the incidence of adverse reactions.2.With the extension of Roxadustat application time,potassium ion level gradually increased,and the potassium ion level was higher than that of r Hu EPO at12 weeks observation.Long-term application of Roxadustat should be vigilant against the occurrence of hyperpotassaemia.3.The efficacy of Roxadustat was better than r Hu EPO in the treatment of patients with non-dialysis-dependent CKD anemia,and there was no significant difference in the incidence of adverse reactions.There was no significant difference between Roxadustat and r Hu EPO in the treatment of dialysis-dependent CKD anemia,but the incidence of adverse reactions of Roxadustat was lower than that of rHuEPO. |
PDF Full Text Request